Arca Biopharma (ABIO) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Arca Biopharma (NASDAQ:ABIO) from a hold rating to a buy rating in a research report released on Thursday.

Shares of ABIO stock traded up $0.09 on Thursday, hitting $0.77. The stock had a trading volume of 1,799,900 shares, compared to its average volume of 901,506. Arca Biopharma has a one year low of $0.45 and a one year high of $2.00.

Arca Biopharma (NASDAQ:ABIO) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07.

About Arca Biopharma

ARCA biopharma, Inc, a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction.

Read More: Trading Strategy Examples and Plans

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply